The Adjuvant Patch: A Universal Dose Sparing Approach for Pandemic and Conventional Vaccines - Preclinical and clinical trials have demonstrated proof-of-concept for the LT-IS patch. - BioPharm

ADVERTISEMENT

The Adjuvant Patch: A Universal Dose Sparing Approach for Pandemic and Conventional Vaccines
Preclinical and clinical trials have demonstrated proof-of-concept for the LT-IS patch.


BioPharm International


23. Ayerst G. Water activity-its measurement and significance in biology. Int. Biodeter. Bull. 1965;1:13–26.

24. United States Pharmacopeia. Application of water activity determination to nonsterile pharmaceutical products. USP 2007 <1112>.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
FDA and NIH Win Award for IP Licensing of Meningitis Vaccine
September 26, 2014
Author Guidelines
Source: BioPharm International,
Click here